Lilly’s experimental shot produced 28% weight loss. That beats Zepbound.

The injection is different than Zepbound and Foundayo.

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro ...

Zepbound vs. Mounjaro For Weight Loss: What’s The Difference?

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...
BioSpace

Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Eli Lilly and its gambit to stay on top of the GLP-1 heap

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has ...
AOL

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a ...
WIBC

Eli Lilly’s Zepbound Vials are Increasing Health Accessibility in Indiana

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health. By combining lower pricing, direct-to ...

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of ...